| ID | Sequence | Length | GC content |
|---|---|---|---|
| SOX2-OT:93 | AAAAAUGUUGAAUAUCAACAAUGGGUUUCAGUGCUGUAUUGUUGAGUUU… | 3427 nt | 0.3636 |
| SOX2-OT:94 | AAAAAUGUUGAAUAUCAACAAUGGGUUUCAGUGCUGUAUUGUUGAGUUU… | 3535 nt | 0.3666 |
| SOX2-OT:95 | AAAAAAAAGAAAAGAAAAAAAAGAGAACCACAGCUUUGGACAAAAGUCU… | 1967 nt | 0.3467 |
| SOX2-OT:96 | CAGUGCAUUUGAAAACUCCCCUUGCACCAGGGCUGACUGUAGCUGGGGG… | 1700 nt | 0.4006 |
| SOX2-OT:97 | AGUGCAUUUGAAAACUCCCCUUGCACCAGGGCUGACUGUAGCUGGGGGA… | 2276 nt | 0.3638 |
| SOX2-OT:98 | AUUUGAAAACUCCCCUUGCACCAGGGCUGACUGUAGCUGGGGGAAGACA… | 989 nt | 0.3953 |
| SOX2-OT:99 | GCUGUAGUGUACUGGCCUAGCUCUAAAACUUUGCAGUACAUCACUUAUU… | 1672 nt | 0.3971 |
This gene produces alternatively spliced long non-coding RNAs. These RNAs were observed to be upregulated in tumor cells and positively correlated to expression of the SRY-box 2 gene. Overexpression of these transcripts may promote cell proliferation. [provided by RefSeq, Dec 2017]
A study in human postmortem brain tissue identified the long noncoding RNA SOX2-OT as being upregulated in the dorsolateral prefrontal cortex of subjects with opioid use disorder compared to non-psychiatric controls [Mendez et al. DOI:10.1038/s41380-021-01259-y].